Communiqués Arecor Therapeutics plc

Actions

AREC

GB00BMWLM973

Recherche biotechnologique et médicale

Temps Différé London S.E. 13:05:29 28/09/2026			Varia. 5j.	Varia. 1 janv.
87,75 ^GBX	-0,85 %		+0,29 %	+9,01 %

13/08	RÉSULTATS ET ACTIVITÉ : tinyBuild poursuit Max Ent ; les pertes de Light Science se creusent	AN
13/08	Arecor Therapeutics plc publie les données cliniques de l'AT278 dans une revue à comité de lecture	CI

Communiqués

25/09/25	Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292	AQ
20/05/24	At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes	AQ
17/05/24	Arecor Therapeutics reports strong 2023 results and outlines expanding product pipeline	AQ
09/05/24	Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery	AQ
14/03/24	Arecor Therapeutics announces collaboration on oral GLP-1 drug for diabetes and obesity treatment	AQ
12/03/24	ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY	AQ
05/12/23	Arecor Therapeutics reveals deal with "global medical products company"	AQ
17/11/23	Arecor Therapeutics takes major step with first commercial sale of AT220	AQ
17/11/23	First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe	AQ
18/09/23	Arecor Therapeutics expecting a busy end to the year after solid first half progress	AQ
20/07/23	Arecor: Business Update	AQ
24/04/23	Arecor Therapeutics has "a strong basis to accelerate" growth strategy	AQ
27/03/23	Arecor Therapeutics gets second phase 1 trial for AT278 underway	AQ
16/02/23	Arecor Therapeutics "confident" in collaboration pipeline after another new deal	AQ
15/11/22	Arecor Therapeutics scientist hopeful that artificial pancreas 'edging closer'	EQ
15/11/22	Arecor Therapeutics scientist hopeful that artificial pancreas "edging closer"	AQ
01/11/22	Tetris Pharma Launches Ogluo® in Germany	BU
11/10/22	Headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247 demonstrate significantly accelerated insulin absorption and early exposure compared to gold standard insulins NovoLog® and Fiasp®	AQ
14/07/22	BUSINESS UPDATE	AQ
18/05/22	ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE	AQ
28/04/22	ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING	AQ
12/04/22	Arecor Announces Oral Presentation at Attd 2022 of Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin for Diabetes	AQ
23/03/22	ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS	AQ
20/01/22	BUSINESS UPDATE	AQ
20/01/22	ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP	GL